Vascular complications in hypertension: The VHAS study

Alberto Zanchetti

Research output: Contribution to journalArticlepeer-review


The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values ≥160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP ≥115 mmHg, and those with diabetes mellitus or previous myocardial infarction or cerebrovascular episodes. Patients were randomly allocated to drug therapy for 2 years with either slow-release verapamil 240 mg once daily or chlorthalidone 25 mg once daily, with nonresponders receiving additional captopril 25 mg daily. A random group of eligible patients (n=494) was followed for a more extended period (4 years) using beta-mode ultrasound. The end point is the development of atherosclerosis detected by ultrasound imaging. The most interesting observation thus far is that in this population of middle-aged hypertensives without a history of previous cardiovascular events, about two thirds had asymptomatic carotid alterations. The study is ongoing.

Original languageEnglish
Pages (from-to)529-531
Number of pages3
JournalCardiovascular Drugs and Therapy
Issue number3 Supplement
Publication statusPublished - Aug 1995


  • atherosclerosis
  • captopril
  • chlorthalidone
  • essential hypertension
  • ultrasound imaging
  • verapamil

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Vascular complications in hypertension: The VHAS study'. Together they form a unique fingerprint.

Cite this